Varsha Singh, Myrna Dolovich, Zhou Xing, Emily D. Cranston and Michael R. Thompson
{"title":"Effect of leucine as an aerosolization enhancer on the bioactivity of spray dried viral-vectored vaccines for inhalation","authors":"Varsha Singh, Myrna Dolovich, Zhou Xing, Emily D. Cranston and Michael R. Thompson","doi":"10.1039/D4PM00079J","DOIUrl":null,"url":null,"abstract":"<p >Aerosolization enhancers, like <small>L</small>-leucine, can improve deep-lung deposition of inhalable dry powders although the implications of their use have not yet been evaluated for sensitive biologics like viral vectored vaccines. This study investigates the effect of <small>L</small>-leucine concentrations (0–50 wt%) as an added component to the viral-encapsulating matrix comprised of mannitol and dextran, on aerosolization relative to bioactivity of spray dried human serotype 5 adenovirus. Modelling the intended purpose of inhalation, the aerodynamic properties (fine particle fraction and mass median aerodynamic diameter) of the powders were analyzed using a Next Generation Impactor. Overall, increasing the <small>L</small>-leucine concentration in the spray dried formulations improved the fine particle fraction (>40%) and reduced the aerodynamic diameter (<5 μm). However, bioactivity was negatively affected by the presence of <small>L</small>-leucine in the formulation and that demanded deeper investigation. The root cause for the declining bioactivity was finally attributed to aggregation of the adenovirus induced by <small>L</small>-leucine in the feed solution prior to spray drying, which was determined using a qViro-X particle counter. The intent of this study was to emphasize that advantages and disadvantages will exist with additives like an aerosolization enhancer, for this relatively new class of vaccines.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 4","pages":" 775-785"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/pm/d4pm00079j?page=search","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RSC Pharmaceutics","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/pm/d4pm00079j","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aerosolization enhancers, like L-leucine, can improve deep-lung deposition of inhalable dry powders although the implications of their use have not yet been evaluated for sensitive biologics like viral vectored vaccines. This study investigates the effect of L-leucine concentrations (0–50 wt%) as an added component to the viral-encapsulating matrix comprised of mannitol and dextran, on aerosolization relative to bioactivity of spray dried human serotype 5 adenovirus. Modelling the intended purpose of inhalation, the aerodynamic properties (fine particle fraction and mass median aerodynamic diameter) of the powders were analyzed using a Next Generation Impactor. Overall, increasing the L-leucine concentration in the spray dried formulations improved the fine particle fraction (>40%) and reduced the aerodynamic diameter (<5 μm). However, bioactivity was negatively affected by the presence of L-leucine in the formulation and that demanded deeper investigation. The root cause for the declining bioactivity was finally attributed to aggregation of the adenovirus induced by L-leucine in the feed solution prior to spray drying, which was determined using a qViro-X particle counter. The intent of this study was to emphasize that advantages and disadvantages will exist with additives like an aerosolization enhancer, for this relatively new class of vaccines.